Table 1.
Baseline characteristics in icotinib primary and acquired resistance EGFR uncommon mutation NSCLC patients
| Characteristic | Primary resistance | Acquired resistance |
|---|---|---|
| N = 21 (%) | N = 48 (%) | |
| Median age (y) | ||
| <65 | 13 (61.90) | 30 (62.5) |
| ≥65 | 8 (38.1) | 18 (37.5) |
| Sex | ||
| Male | 10 (47.62) | 21 (43.8) |
| Female | 11 (52.38) | 27 (56.2) |
| Smoking status | ||
| Present or former smoker | 5 (23.81) | 14 (29.2) |
| Non–smoker | 16 (76.19) | 34 (70.8) |
| ECOG PS | ||
| 0‐1 | 18 (85.71) | 40 (83.3) |
| 2‐3 | 3 (14.29) | 8 (16.7) |
| Histology | ||
| Adenocarcinoma | 17 (80.95) | 45 (93.8) |
| Non–adenocarcinoma | 4 (19.05) | 3 (6.2) |
| Treatment lines | ||
| First | 0 (0) | 1 (2.1) |
| Second | 1 (4.76) | 4 (8.3) |
| Third and more | 20 (95.24) | 43 (89.6) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; NSCLC, non–small cell lung cancer.